Global marketsUpdated November 12
A Hill opinion says rare risks matter at scale.
A Hill opinion makes a point about scale: even an uncommon complication could affect many people when a medication is prescribed to millions. Its title applies that concern to the risk of blindness from GLP-1 drugs. That is an argument for taking a possible risk seriously, not a new finding that the drugs cause NAION.
1 publisher1 report
Coverage started November 12
Key Actors
- Novo
- United States Food and Drug Administration
